Owen Hughes


Owen Hughes is the CEO of Sail Bio, a company looking to address toxic proteinopathies and the former CEO and co-founder of Cullinan Oncology (NASDAQ: CGEM), a hub-n-spoke enterprise focused on developing novel cancer therapeutics.  Prior to Cullinan, Owen served as the CBO and Head of Corporate Development for Intarcia Therapeutics.

Owen started his career on Wall Street, initially in equity research at Morgan Stanley before transitioning to the buyside, where he managed public and private healthcare investments for Brookside Capital, a hedge fund under the Bain Capital umbrella and Pyramis Advisors, a Fidelity Investments company.

Owen served as the Chairman of Radius Health (NASDAQ: RDUS) until its sale to Gurnet Point Capital and Patient Square Capital and was formerly the lead independent director for Translate Bio (NASDAQ: TBIO) until its acquisition by Sanofi.

Scroll to Top